Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

Diabetes Care ◽

10.2337/dc20-0763 ◽

2021 ◽

pp. dc200763

Author(s):

Julie Dubourg ◽

Pascale Fouqueray ◽

Carole Thang ◽

Jean-Marie Grouin ◽

Kohjiro Ueki

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Multicenter Phase ◽

Parallel Group

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study

10.1111/dom.13079 ◽

2017 ◽

Vol 20 (2) ◽

pp. 453-457 ◽

Cited By ~ 15

Author(s):

Takashi Kadowaki ◽

Nobuya Inagaki ◽

Kazuoki Kondo ◽

Kenichi Nishimura ◽

Genki Kaneko ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Comparative Study ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study

Current Medical Research and Opinion ◽

10.1185/03007995.2014.909390 ◽

2014 ◽

Vol 30 (7) ◽

pp. 1231-1244 ◽

Cited By ~ 30

Author(s):

Yutaka Seino ◽

Takashi Sasaki ◽

Atsushi Fukatsu ◽

Michito Ubukata ◽

Soichi Sakai ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Ii Study ◽

Japanese Patients ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo ◽

Finding Study ◽

Dose Finding Study

Decision letter for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v1/review2 ◽

2019 ◽

Author(s):

Bastiaan E de Galan

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial

10.1111/j.1463-1326.2012.01662.x ◽

2012 ◽

Vol 14 (11) ◽

pp. 1040-1046 ◽

Cited By ~ 51

Author(s):

T. Eto ◽

S. Inoue ◽

T. Kadowaki

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Controlled Trial ◽

Blood Glucose Control ◽

Japanese Patients ◽

Double Blind ◽

Once Daily ◽

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

10.1111/dom.12047 ◽

2013 ◽

Vol 15 (5) ◽

pp. 432-440 ◽

Cited By ~ 90

Author(s):

K. Kaku ◽

S. Inoue ◽

O. Matsuoka ◽

A. Kiyosue ◽

H. Azuma ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Glycaemic Control ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study

10.1111/dom.12555 ◽

2015 ◽

Vol 17 (12) ◽

pp. 1198-1201 ◽

Cited By ~ 5

Author(s):

K. Kaku ◽

M. Katou ◽

M. Igeta ◽

T. Ohira ◽

H. Sano

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Comparative Study ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Parallel Group

Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes

Clinical Therapeutics ◽

10.1016/j.clinthera.2007.01.003 ◽

2007 ◽

Vol 29 (1) ◽

pp. 74-83 ◽

Cited By ~ 162

Author(s):

Franklin J. Zieve ◽

Marcia F. Kalin ◽

Sherwyn L. Schwartz ◽

Michael R. Jones ◽

William L. Bailey

Keyword(s):

Type 2 Diabetes ◽

Pilot Study ◽

Glycemic Control ◽

Double Blind ◽

Glucose Lowering ◽

Double Blind Placebo ◽

Lowering Effect ◽

Glucose Lowering Effect

1089-P: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of HD-6277, a Potent and Selective G-Protein-Coupled Receptor 40 (GPR40) Agonist, in Patients with Type 2 Diabetes Mellitus

Diabetes ◽

10.2337/db20-1089-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 1089-P

Author(s):

KI-HWAN KIM ◽

HYE-JUNG YANG ◽

MYOUNGKI BAEK

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

G Protein ◽

Phase 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Study ◽

G Protein Coupled